167.47
price down icon0.50%   -0.84
after-market 시간 외 거래: 167.47
loading
전일 마감가:
$168.31
열려 있는:
$169.98
하루 거래량:
421.93K
Relative Volume:
0.94
시가총액:
$10.24B
수익:
$393.98M
순이익/손실:
$-367.45M
주가수익비율:
-26.61
EPS:
-6.293
순현금흐름:
$-460.07M
1주 성능:
-1.43%
1개월 성능:
-3.20%
6개월 성능:
+30.63%
1년 성능:
+24.62%
1일 변동 폭
Value
$166.82
$175.88
1주일 범위
Value
$165.24
$175.88
52주 변동 폭
Value
$111.09
$183.00

Ascendis Pharma A S Adr Stock (ASND) Company Profile

Name
명칭
Ascendis Pharma A S Adr
Name
전화
-
Name
주소
-
Name
직원
1,017
Name
트위터
Name
다음 수익 날짜
2024-12-13
Name
최신 SEC 제출 서류
Name
ASND's Discussions on Twitter

ASND을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ASND
Ascendis Pharma A S Adr
167.47 10.18B 393.98M -367.45M -460.07M -6.293
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-03 재개 Morgan Stanley Overweight
2025-05-05 업그레이드 Morgan Stanley Equal-Weight → Overweight
2025-04-16 개시 RBC Capital Mkts Outperform
2025-01-07 개시 UBS Buy
2024-09-05 업그레이드 Oppenheimer Perform → Outperform
2024-06-25 업그레이드 TD Cowen Hold → Buy
2024-05-31 개시 Stifel Buy
2023-12-20 개시 Jefferies Buy
2023-06-14 재개 Credit Suisse Neutral
2023-04-05 다운그레이드 Oppenheimer Outperform → Perform
2023-04-04 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2023-04-03 다운그레이드 Credit Suisse Outperform → Neutral
2022-10-20 개시 Goldman Buy
2022-08-30 재개 Berenberg Buy
2022-03-28 재개 Wedbush Outperform
2022-03-15 업그레이드 BofA Securities Neutral → Buy
2022-03-01 개시 Citigroup Buy
2022-02-14 업그레이드 Oppenheimer Perform → Outperform
2022-01-06 개시 Cowen Market Perform
2021-12-08 개시 Wells Fargo Overweight
2021-10-20 다운그레이드 BofA Securities Buy → Neutral
2021-03-30 다운그레이드 Oppenheimer Outperform → Perform
2021-03-11 재개 Stifel Buy
2020-12-17 개시 Berenberg Buy
2020-09-14 재개 JP Morgan Overweight
2020-03-20 개시 Oppenheimer Outperform
2019-10-11 개시 Morgan Stanley Overweight
2019-03-25 개시 Evercore ISI Outperform
2019-01-24 개시 Cantor Fitzgerald Overweight
2019-01-24 업그레이드 Leerink Partners Mkt Perform → Outperform
2018-06-26 개시 Stifel Buy
2018-04-02 재확인 Leerink Partners Mkt Perform
2017-05-11 개시 JP Morgan Overweight
2017-03-09 다운그레이드 Leerink Partners Outperform → Mkt Perform
2017-02-09 개시 Credit Suisse Outperform
2016-09-26 개시 Wedbush Outperform
모두보기

Ascendis Pharma A S Adr 주식(ASND)의 최신 뉴스

pulisher
Jul 25, 2025

Stocks Showing Rising Market Leadership: Gpo Aeroportuario ADR Earns 83 RS Rating - inkl

Jul 25, 2025
pulisher
Jul 24, 2025

Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 81 RS Rating - MSN

Jul 24, 2025
pulisher
Jul 14, 2025

Ascendis Pharma reports positive results from hypothyroid trial - MSN

Jul 14, 2025
pulisher
Jul 02, 2025

Ascendis Pharma stock rating assumed at Overweight by Morgan Stanley - Investing.com

Jul 02, 2025
pulisher
Jun 30, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Jun 30, 2025
pulisher
Jun 26, 2025

European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize

Jun 26, 2025
pulisher
Jun 10, 2025

Canaccord holds Ascendis Pharma stock at $84 target - Investing.com

Jun 10, 2025
pulisher
Jun 10, 2025

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Galapagos (GLPG) and Tenet Healthcare (THC) - The Globe and Mail

Jun 10, 2025
pulisher
Jun 09, 2025

BofA raises Ascendis Pharma stock target to $216 - Investing.com

Jun 09, 2025
pulisher
Jun 04, 2025

Ascendis Pharma ADR Scores Relative Strength Rating Upgrade - MSN

Jun 04, 2025
pulisher
Jun 03, 2025

Chagee Holdings ADR Scores Relative Strength Rating Upgrade - inkl

Jun 03, 2025
pulisher
Jun 02, 2025

BofA Securities raises Ascendis Pharma stock price target to $201 - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

European ADRs Climb With Biotech Stocks Leading The Charge - Finimize

Jun 02, 2025
pulisher
Jun 02, 2025

Ascendis Pharma stock rises following FDA priority review By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

Ascendis Pharma stock rises following FDA priority review - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

FDA prioritizes review of Ascendis Pharma’s growth disorder drug - Investing.com

Jun 02, 2025
pulisher
May 27, 2025

Stifel maintains Buy on Ascendis Pharma stock, target at $212 - Investing.com

May 27, 2025
pulisher
May 25, 2025

Ascendis Pharma’s SWOT analysis: strong product pipeline drives stock potential - Investing.com India

May 25, 2025
pulisher
May 15, 2025

Ascendis Pharma grants new employee warrants By Investing.com - Investing.com India

May 15, 2025
pulisher
May 14, 2025

Ascendis Pharma grants new employee warrants - Investing.com

May 14, 2025
pulisher
May 13, 2025

Ascendis Pharma reports growth in achondroplasia trial By Investing.com - Investing.com India

May 13, 2025
pulisher
May 13, 2025

Ascendis Pharma reports growth in achondroplasia trial - Investing.com

May 13, 2025
pulisher
May 12, 2025

Cantor maintains $200 target on Ascendis Pharma stock By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 09, 2025

European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize

May 09, 2025
pulisher
May 08, 2025

In the Green: Ascendis Pharma A/S ADR (ASND) Closes at 160.99, Up/Down -1.14 from Previous Day - DWinneX

May 08, 2025
pulisher
May 02, 2025

Ascendis Pharma stock target raised to $245 by JPMorgan - Investing.com

May 02, 2025
pulisher
May 02, 2025

Ascendis Pharma A/S ADR (ASND) stock on the rise: An overview - uspostnews.com

May 02, 2025
pulisher
May 01, 2025

Ascendis Pharma AS earnings missed by €0.11, revenue topped estimates - Investing.com

May 01, 2025
pulisher
Apr 30, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 30, 2025
pulisher
Apr 16, 2025

RBC Capital sets $205 target on Ascendis Pharma stock - Investing.com

Apr 16, 2025
pulisher
Apr 15, 2025

Banco Macro ADR Earns Relative Strength Rating Upgrade - inkl

Apr 15, 2025
pulisher
Apr 14, 2025

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 11, 2025

Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily

Apr 11, 2025
pulisher
Apr 11, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Jump To 87 - Investor's Business Daily

Apr 11, 2025
pulisher
Apr 07, 2025

European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView

Apr 07, 2025
pulisher
Mar 27, 2025

UBS maintains Ascendis Pharma stock Buy rating, $196 target - Investing.com

Mar 27, 2025
pulisher
Mar 19, 2025

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView

Mar 19, 2025
pulisher
Mar 18, 2025

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Mar 18, 2025
pulisher
Mar 17, 2025

European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView

Mar 17, 2025
pulisher
Mar 13, 2025

European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView

Mar 13, 2025
pulisher
Mar 12, 2025

European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView

Mar 12, 2025
pulisher
Mar 09, 2025

Ascendis Pharma A/S Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 07, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView

Mar 07, 2025
pulisher
Mar 06, 2025

Ascendis Pharma at TD Cowen Conference: Strategic Growth in Rare Diseases - Investing.com

Mar 06, 2025
pulisher
Feb 26, 2025

Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com

Feb 26, 2025
pulisher
Feb 25, 2025

Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com

Feb 25, 2025
pulisher
Feb 20, 2025

Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga

Feb 20, 2025
pulisher
Feb 20, 2025

Stocks To Watch: Kontoor Brands Sees RS Rating Rise To 84 - Inkl

Feb 20, 2025
pulisher
Feb 19, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 82 - Investor's Business Daily

Feb 19, 2025
pulisher
Feb 18, 2025

Stocks To Watch: Pony AI ADR Sees RS Rating Jump To 92 - Inkl

Feb 18, 2025

Ascendis Pharma A S Adr (ASND) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
자본화:     |  볼륨(24시간):